Study of bemotuzumab plus chemo and anlotinib for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of the targeted drug bemotuzumab, chemotherapy, and anlotinib (which blocks blood vessel growth) followed by radiation therapy for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this approach helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have extensive-stage small cell lung cancer that has spread beyond one lung.
- You have not had any previous treatment for this stage of cancer.
- You are between 18 and 75 years old.
- You are able to do your daily activities with little help (ECOG score 0-2).
- Your major organs (kidneys, liver, heart, blood) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of two drugs for people with extensive-stage small cell lung cancer that has stopped responding to at least two previous treatments. The goal is to see if this combination can help control the cancer when other options have failed.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This study tests a combination of three drugs (bevacizumab, anlotinib, and etoposide) as the first treatment for small-cell lung cancer that has spread. It is designed for older patients or those who cannot tolerate standard intensive chemotherapy, with the goal of controlling the cancer while being gentler on the body.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.